サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1124829

ゲノムシーケンシングの世界市場 (～2027年)：ヌクレオチド配列・技術・用途・エンドユーザー・地域別の競合予測・機会

Global Genome Sequencing Market, By Nucleotide Sequenced, By Technique, By Application, By End User, By Region Competition Forecast and Opportunities, 2027
出版日: | 発行: TechSci Research | ページ情報: 英文 111 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

ゲノムシーケンシングの世界市場 (～2027年)：ヌクレオチド配列・技術・用途・エンドユーザー・地域別の競合予測・機会
出版日: 2022年09月01日
発行: TechSci Research
ページ情報: 英文 111 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のゲノムシーケンシングの市場は遺伝子シーケンシングとバイオインフォマティクスにおける技術的進歩の高まりを背景に、予測期間中に高いCAGRで成長すると予想されています。

先進的な医薬品に対する需要の急増や進化する感染症も今後5年間における市場成長をさらに後押しする見通しです。また、政府からの安定した資金供給と技術研究範囲の拡大も今後5年間の市場成長をサポートしています。さらに、癌の罹患率の増加や癌研究における次世代シーケンサー用途の増加、ゲノム産業における新規事業者やスタートアップ企業の参入などもさらなる市場成長の機会を示しています。

当レポートでは、世界のゲノムシーケンシングの市場を調査し、市場概要、市場規模の推移・予測、各種区分・地域/主要国別の内訳、市場への各種影響因子の分析、競合環境、市場シェア、主要企業のプロファイルなどをまとめています。

目次

第1章 製品概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19：世界のゲノムシーケンシング市場に与える影響

第5章 VOC (顧客の声)

第6章 世界のゲノムシーケンシング市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • ヌクレオチド配列別（DNA・RNA）
    • 技術別（次世代シーケンシング・PCR・マイクロアレイ技術・その他）
    • 用途別（診断・創薬&開発・精密医療・その他）
    • エンドユーザー別（学術&研究機関・製薬&バイオテクノロジー企業・病院&診療所・その他）
    • 企業別
    • 地域別
  • 製品市場マップ

第8章 北米のゲノムシーケンシング市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • ヌクレオチド配列別
    • 技術別
    • 用途別
    • エンドユーザー別
    • 国別
  • 国別分析

第8章 欧州のゲノムシーケンシング市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • ヌクレオチド配列別
    • 技術別
    • 用途別
    • エンドユーザー別
    • 国別
  • 国別分析

第9章 アジア太平洋のゲノムシーケンシング市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • ヌクレオチド配列別
    • 技術別
    • 用途別
    • エンドユーザー別
    • 国別
  • 国別分析

第10章 南米のゲノムシーケンシング市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • ヌクレオチド配列別
    • 技術別
    • 用途別
    • エンドユーザー別
    • 国別
  • 国別分析

第11章 中東およびアフリカのゲノムシーケンシング市場の見通し

  • 市場規模・予測
  • 市場シェア・予測
    • ヌクレオチド配列別
    • 技術別
    • 用途別
    • エンドユーザー別
    • 国別
  • 国別分析

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場動向・市場展開

第14章 競合情勢

  • 企業プロファイル
  • Thermo Fisher Scientific, Inc.
  • Ilumina, Inc.
  • QIAGEN N.V.
  • Eurofins Scientific SE
  • Agilent Technologies, Inc.
  • Oxford Nanopore Technologies Limited
  • F. Hoffmann-La Roche AG
  • Bio-Rad Laboratories, Inc.
  • Abbott Laboratories, Inc.
  • Danaher Corporation

第15章 戦略的提言

目次
Product Code: 10656

Global genome sequencing market is anticipated to grow with an impressive CAGR during the forecast years on the grounds of growing technological advancement in genetic sequencing and bioinformatics. Surge in the demand for the advanced pharmaceuticals and evolving infectious diseases further drive the growth of the global genome sequencing market in the upcoming five years. With consistent supply of financial funds from the government and higher research scope in the technology also supports the growth of the global genome sequencing market in the next five years. Moreover, growing instances of cancer and increasing applications of next generation sequencing in cancer research, the entry of new players and start-ups in the genomics industry further substantiates the growth of the global genome sequencing market in the forecast years.

Genome sequencing is a form of genetic engineering tool that can be defined as the method of identification and analysis of the genetic material found in any living organisms. Sequencing is basically identifying the DNA or RNA mapping sequences to diagnose the function of the translated protein and its effect on the organisms. The genome sequencing helps in identifying the threat or the properties of the evolution of the organisms. The process becomes highly apt for the healthcare processes where identification of the disease causing microorganisms can be carried out and design effective pharmaceutical and therapeutics along with precision medicine to treat these diseases.

Pharmaceutical Evolution Drives Market Growth

Increasing instances of infectious diseases and surge in the demands for the effective vaccinations and pharmaceutical products actively drive the growth of the global genome sequencing market in the upcoming five years. Application of genome sequencing for drug discovery and development increased in the recent years owing to the pandemic conditions caused due to viral infection of COVID-19. Sudden demand for the vaccination and treatment pharmaceuticals and therapeutics further aided to the growth of the global genome sequencing market in the future five years.

Detailed study on the genome (RNA) of the SARS-CoV-2 virus was conducted and multiple market players with the financial aids from the government discovered effective vaccine against the infection. High investments, reliability of the procedure, along with the threat of lost lives due to COVID-19 played major role in the recent developments in the genome sequencing thereby substantiating the growth of the global genome sequencing market in the forecast years. Government authorities like National Institutes for Health in the United States invested USD4435 Million in total human genome project that would be utilized for the further advancement of genome sequencing procedures.

Diagnostic Advances Through Genome Sequencing

Genome sequencing also allows detailed diagnosis of the organisms and their functions. Advancement in the biotechnological procedures and microbiology studies add to the growth of the global genome sequencing market in the upcoming five years. Procedures like next generation sequencing might be expensive but it provides simultaneous analysis of many genomic loci while revealing the exact sequence changes. For the diagnosis of cancer at early stage and to identify the complication of the chronic disease, the process allows clinicians to test many genes of a cancer simultaneously. The process has multiple advantages like ultra-high throughput, scalability, and speed, thus stimulating further demands and substantiating the market growth. The process is also actively utilized in next generation therapeutics development.

Higher prevalence of genetic mutations and environmental factors that play right into evolving the DNA or RNA of the organisms, require highly capable procedures of sequencing such that advancing and evolving genomes could be mapped. Identification of organisms is not only beneficial in case of diseases, but also to map the variants of species alive, thereby academic growth in the sequencing further facilitates the growth of the global genome sequencing market in the upcoming five years.

Market Segmentation

The global genome sequencing market segmentation is based on nucleotide sequenced, technique, application, end user, regional distribution, and competitive landscape. Based on nucleotide sequenced, the market is differentiated between DNA and RNA. By technique, the market is further segmented into next generation sequencing, PCR, microarray technology, and others. Based on application, the market is bifurcated into diagnostics, drug discovery & development, precision medicine, and others. By end user, the market is fragmented into academic & research institutions, pharmaceutical & biotechnology companies, hospitals & clinics, and others. The market analysis also studies the regional segmentation, divided among Asia-Pacific region, North American region, European region, South American region, and Middle East & African region.

Company Profile

Thermo Fisher Scientific, Inc., Ilumina, Inc., QIAGEN N.V., Eurofins Scientific SE, Agilent Technologies, Inc., Oxford Nanopore Technologies Limited, F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Abbott Laboratories, Inc., Danaher Corporation, are enlisted in a partial list of major market players of the global genome sequencing market.

Years considered for this report:

Historical Years: 2017-2020

Base Year: 2021

Estimated Year: 2022

Forecast Period: 2023-2027

Report Scope:

In this report, global genome sequencing market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Genome Sequencing Market, By Nucleotide Sequenced:

DNA

RNA

  • Genome Sequencing Market, By Technique:

Next Generation Sequencing

Polymerase Chain Reaction (PCR)

Microarray Technology

Others

  • Genome Sequencing Market, By Application:

Diagnostics

Drug Discovery & Development

Precision Medicine

Others

  • Genome Sequencing Market, By End User:

Academic & Research Institutions

Pharmaceutical & Biotechnology Companies

Hospitals & Clinics

Others

  • Genome Sequencing Market, By Region:

North America

  • United States
  • Mexico
  • Canada

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Australia

Europe

  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain

South America

  • Brazil
  • Argentina
  • Colombia

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global genome sequencing market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Genome Sequencing Market

5. Voice of Customer

  • 5.1. Factors Contributing to Demand for Genome Sequencing
  • 5.2. Source of Information
  • 5.3. Commonly Sequenced Nucleotides
  • 5.4. Preference, By Technique
  • 5.5. Demand, By Application
  • 5.6. Brand Awareness

6. Global Genome Sequencing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Nucleotide Sequenced (DNA v/s RNA)
    • 6.2.2. By Technique (Next Generation Sequencing, PCR, Microarray Technology, Others)
    • 6.2.3. By Application (Diagnostics, Drug Discovery & Development, Precision Medicine, Others)
    • 6.2.4. By End User (Academic & Research Institutions, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Others)
    • 6.2.5. By Company (2021)
    • 6.2.6. By Region
  • 6.3. Product Market Map

7. North America Genome Sequencing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Nucleotide Sequenced
    • 7.2.2. By Technique
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Genome Sequencing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Nucleotide Sequenced
        • 7.3.1.2.2. By Technique
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. Mexico Genome Sequencing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Nucleotide Sequenced
        • 7.3.2.2.2. By Technique
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. Canada Genome Sequencing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Nucleotide Sequenced
        • 7.3.3.2.2. By Technique
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User

8. Europe Genome Sequencing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Nucleotide Sequenced
    • 8.2.2. By Technique
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Genome Sequencing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Nucleotide Sequenced
        • 8.3.1.2.2. By Technique
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. Germany Genome Sequencing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Nucleotide Sequenced
        • 8.3.2.2.2. By Technique
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. United Kingdom Genome Sequencing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Nucleotide Sequenced
        • 8.3.3.2.2. By Technique
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. Italy Genome Sequencing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Nucleotide Sequenced
        • 8.3.4.2.2. By Technique
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Spain Genome Sequencing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Nucleotide Sequenced
        • 8.3.5.2.2. By Technique
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. Asia-Pacific Genome Sequencing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Nucleotide Sequenced
    • 9.2.2. By Technique
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Genome Sequencing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Nucleotide Sequenced
        • 9.3.1.2.2. By Technique
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. India Genome Sequencing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Nucleotide Sequenced
        • 9.3.2.2.2. By Technique
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. South Korea Genome Sequencing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Nucleotide Sequenced
        • 9.3.3.2.2. By Technique
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User
    • 9.3.4. Japan Genome Sequencing Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Nucleotide Sequenced
        • 9.3.4.2.2. By Technique
        • 9.3.4.2.3. By Application
        • 9.3.4.2.4. By End User
    • 9.3.5. Australia Genome Sequencing Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Nucleotide Sequenced
        • 9.3.5.2.2. By Technique
        • 9.3.5.2.3. By Application
        • 9.3.5.2.4. By End User

10. South America Genome Sequencing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Nucleotide Sequenced
    • 10.2.2. By Technique
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Genome Sequencing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Nucleotide Sequenced
        • 10.3.1.2.2. By Technique
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Argentina Genome Sequencing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Nucleotide Sequenced
        • 10.3.2.2.2. By Technique
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. Colombia Genome Sequencing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Nucleotide Sequenced
        • 10.3.3.2.2. By Technique
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Middle East and Africa Genome Sequencing Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Nucleotide Sequenced
    • 11.2.2. By Technique
    • 11.2.3. By Application
    • 11.2.4. By End User
    • 11.2.5. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Genome Sequencing Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Nucleotide Sequenced
        • 11.3.1.2.2. By Technique
        • 11.3.1.2.3. By Application
        • 11.3.1.2.4. By End User
    • 11.3.2. Saudi Arabia Genome Sequencing Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Nucleotide Sequenced
        • 11.3.2.2.2. By Technique
        • 11.3.2.2.3. By Application
        • 11.3.2.2.4. By End User
    • 11.3.3. UAE Genome Sequencing Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Nucleotide Sequenced
        • 11.3.3.2.2. By Technique
        • 11.3.3.2.3. By Application
        • 11.3.3.2.4. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Company Profiles
    • 14.1.1. Company Details
    • 14.1.2. Financials (As reported)
    • 14.1.3. Key Market Focus and Geographical Presence
    • 14.1.4. Pricing of Target Products
    • 14.1.5. Market positioning
  • 14.2. Thermo Fisher Scientific, Inc.
  • 14.3. Ilumina, Inc.
  • 14.4. QIAGEN N.V.
  • 14.5. Eurofins Scientific SE
  • 14.6. Agilent Technologies, Inc.
  • 14.7. Oxford Nanopore Technologies Limited
  • 14.8. F. Hoffmann-La Roche AG
  • 14.9. Bio-Rad Laboratories, Inc.
  • 14.10. Abbott Laboratories, Inc.
  • 14.11. Danaher Corporation

15. Strategic Recommendations

(Note: The companies list can be customized based on the client requirements.)